We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

An Evaluation of PDI-320 in Comparison to Its Monads in Adults With Rosacea

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2014 by PreCision Dermatology, Inc..
Recruitment status was:  Active, not recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01828177
First Posted: April 10, 2013
Last Update Posted: May 29, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
PreCision Dermatology, Inc.
  Purpose
This 4-arm Phase 2 vehicle-controlled study is designed to assess the safety and efficacy of PDI-320, and the individual components, in adult subjects with rosacea.

Condition Intervention Phase
Rosacea Drug: PDI-320 Drug: PDI-320 Monad #1 Drug: PDI-320 Monad #2 Drug: Vehicle Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter Randomized Evaluator-Blinded Vehicle-Controlled Parallel Group Evaluation of Twice Daily PDI-320 in Comparison to Its Monads in Adults With Rosacea

Resource links provided by NLM:


Further study details as provided by PreCision Dermatology, Inc.:

Primary Outcome Measures:
  • Treatment "Success Rate" based on change in Investigator's Global Assessment (IGA) [ Time Frame: Baseline and End of Treatment (up to 12 weeks) ]
    IGA Score Success Rate is defined as the percentage of subjects who achieve "Clear" (score = 0) or "Almost Clear" (score = 1) and have at least a 2-grade improvement on the IGA score at the End of Treatment. IGA score is used to evaluate the overall severity of rosacea using a 5-point scale from 0 (clear) to 4 (severe).

  • Absolute change in inflammatory lesion count [ Time Frame: Baseline and End of Treatment (up to 12 weeks) ]
    Inflammatory lesions include papules and pustules on the face, and are counted by study personnel.


Secondary Outcome Measures:
  • Treatment "Success Rate" based on change in IGA (interim time points) [ Time Frame: Baseline, Week 4 and Week 8 ]
    IGA Score Success Rate is the same as defined in the Primary Outcome Measures.

  • Absolute change in inflammatory lesion count (interim time points) [ Time Frame: Baseline, Week 4 and Week 8 ]
    Inflammatory lesions include papules and pustules on the face, and are counted by study personnel.

  • Change in erythema severity [ Time Frame: Baseline and End of Treatment (up to 12 weeks) ]
    The investigator will assess the erythema (skin redness) on the entire face, using a grading scale from 0 (none) to 4 (very severe)

  • Change in telangiectasia severity [ Time Frame: Baseline and End of Treatment (up to 12 weeks) ]
    The investigator will assess telangiectasia (small dilated blood vessels near the surface of the skin) on the face, using a grading scale of 0 (none) to 3 (severe).


Estimated Enrollment: 200
Study Start Date: June 2013
Estimated Study Completion Date: June 2014
Estimated Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: PDI-320
Foam, twice daily for up to 12 weeks
Drug: PDI-320
Experimental: PDI-320 Monad #1
Foam, twice daily for up to 12 weeks
Drug: PDI-320 Monad #1
Experimental: PDI-320 Monad #2
Foam, twice daily for up to 12 weeks
Drug: PDI-320 Monad #2
Placebo Comparator: Vehicle
Foam, twice daily for up to 12 weeks
Drug: Vehicle

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject has moderate to severe papulopustular rosacea and at least mild erythema and mild telangiectasia.
  • Subject is willing and able to apply the test article(s) as directed, comply with study instructions and commit to all follow-up visits for the duration of the study.
  • If subject is a woman of childbearing potential, she must have a negative urine pregnancy test and agree to use an effective form of birth control for the duration of the study.

Exclusion Criteria:

  • Subject is pregnant, lactating or is planning to become pregnant during the study.
  • Subject has any other active dermatological condition on the face that may interfere with the conduct of the study.
  • Subject has used systemic immunosuppressants within 30 days prior to study start.
  • Subject has used systemic retinoids within 6 months prior to study start.
  • Subject has used any topical rosacea therapy within 14 days prior to study start.
  • Subject has had laser or light therapy on the face within 3 months of study start.
  • Subject is currently enrolled in an investigational drug or device study.
  • Subject has used an investigational drug or investigational device treatment within 30 days prior to first application of the test article.
  • Subject has used vasodilators or adrenergic blocking agents within 6 weeks of study start (except subjects on stable dose for greater than 3 months).
  • Subject has active ocular rosacea and/or blepharitis/meibomianitis requiring treatment by an ophthalmologist.
  • Subject has previously failed to have improvement of rosacea with appropriate use of systemic tetracycline family of antibiotics or use of the components of PDI-320.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01828177


Locations
United States, California
Therapeutics Clinical Research
San Diego, California, United States
United States, New Mexico
Academic Dermatology Associates
Albuquerque, New Mexico, United States
Sponsors and Collaborators
PreCision Dermatology, Inc.
Investigators
Study Director: Syd Dromgoole, PhD Therapeutics, Inc.
  More Information

Responsible Party: PreCision Dermatology, Inc.
ClinicalTrials.gov Identifier: NCT01828177     History of Changes
Other Study ID Numbers: 172-7451-201
First Submitted: April 3, 2013
First Posted: April 10, 2013
Last Update Posted: May 29, 2014
Last Verified: May 2014

Keywords provided by PreCision Dermatology, Inc.:
PreCision
PDI-320
Foam

Additional relevant MeSH terms:
Rosacea
Skin Diseases